BioSpace News Archive

Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced it will officially unveil the VITROS® XT 7600 Integrated System*, now available in numerous countries that accept CE Mark, at the 2018 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo. It also will present seven scientific posters highlighting...

SomaGenics, Inc. announces the award of a three-year, $2.9 million NIH grant in support of its Hepatitis Delta Virus (HDV) therapeutic program under Principal Investigator and SomaGenics CEO Brian H. Johnston, Ph.D.

I-Mab and ABL Bio will collaborate on three novel Bispecific Antibodies (BsAbs) while ABL Bio is licensing additional I-Mab antibody sequences for development using ABL Bio’s BsAb platform.

ZOLL® Medical Corporation announced today that it was awarded $1.8 million in damages plus $3.6 million in attorneys’ fees, costs and interest for breach of contract by AutoMedx, LLC.

Quanterix Corporation announced that Kevin Hrusovsky, Chief Executive Officer, President and Chairman of Quanterix, will present at the Canaccord Genuity 38th Annual Growth Conference, on Thursday, Aug. 9, 2018 at 10 a.m., EDT at the InterContinental Boston.

Tissue Source is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI).

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. (“Tetraphase” or the “Company”) (NASDAQ: TTPH) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Tetraphase securities: 1) pursuant and/or traceable to its registration statement and prospectus issued in connection with the its July 2017

BlueWind Medical announced today the appointment of Dr. Roger R. Dmochowski of Vanderbilt University as the company’s chief medical officer (CMO).

A poster presented at the Texas Transplant Society (TTS), “Better Predictions of Kidney Transplant Outcomes with Artificial Intelligence,” found that HealthTech Solutions’ TXP ChatTM could significantly improve predictions of kidney transplant outcomes compared to more traditional methods of deceased donor organ assessment and potential patient match.

Phosphorus, a leader in diagnostic and bioinformatic solutions for clinical Next Generation Sequencing (NGS), announced today that Mark McDonough, most recently chief executive officer of CombiMatrix, has been named chief business officer.